Traws Pharma (TRAW) Competitors $2.30 -0.10 (-4.17%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$2.30 0.00 (-0.04%) As of 03/31/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW vs. BRNS, LTRN, XLO, ATRA, SCYX, DYAI, FBLG, MDCX, PRLD, and SRZNShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Barinthus Biotherapeutics (BRNS), Lantern Pharma (LTRN), Xilio Therapeutics (XLO), Atara Biotherapeutics (ATRA), SCYNEXIS (SCYX), Dyadic International (DYAI), FibroBiologics (FBLG), Medicus Pharma (MDCX), Prelude Therapeutics (PRLD), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. Barinthus Biotherapeutics Lantern Pharma Xilio Therapeutics Atara Biotherapeutics SCYNEXIS Dyadic International FibroBiologics Medicus Pharma Prelude Therapeutics Surrozen Barinthus Biotherapeutics (NASDAQ:BRNS) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation. Do analysts rate BRNS or TRAW? Barinthus Biotherapeutics presently has a consensus target price of $5.17, indicating a potential upside of 431.17%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Barinthus Biotherapeutics is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of BRNS or TRAW? 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 7.9% of Traws Pharma shares are held by institutional investors. 8.0% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 13.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor BRNS or TRAW? Barinthus Biotherapeutics received 16 more outperform votes than Traws Pharma when rated by MarketBeat users. CompanyUnderperformOutperformBarinthus BiotherapeuticsOutperform Votes16100.00% Underperform VotesNo VotesTraws PharmaN/AN/A Does the media prefer BRNS or TRAW? In the previous week, Traws Pharma had 15 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 18 mentions for Traws Pharma and 3 mentions for Barinthus Biotherapeutics. Traws Pharma's average media sentiment score of 0.23 beat Barinthus Biotherapeutics' score of 0.16 indicating that Traws Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Barinthus Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Traws Pharma 0 Very Positive mention(s) 2 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BRNS or TRAW more profitable? Barinthus Biotherapeutics has a net margin of 0.00% compared to Traws Pharma's net margin of -62,294.25%. Traws Pharma's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Barinthus BiotherapeuticsN/A -34.26% -29.30% Traws Pharma -62,294.25%N/A -822.38% Which has higher valuation & earnings, BRNS or TRAW? Traws Pharma has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBarinthus Biotherapeutics$14.97M2.61-$73.35M-$1.55-0.63Traws Pharma$226K37.16-$18.95M-$141.56-0.02 Which has more risk & volatility, BRNS or TRAW? Barinthus Biotherapeutics has a beta of -0.8, suggesting that its stock price is 180% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. SummaryBarinthus Biotherapeutics beats Traws Pharma on 9 of the 17 factors compared between the two stocks. Remove Ads Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.40M$6.90B$5.64B$7.79BDividend YieldN/A2.81%5.34%4.03%P/E Ratio-0.027.4223.6318.68Price / Sales37.16207.00370.1589.76Price / CashN/A65.6738.1734.64Price / Book0.186.206.744.12Net Income-$18.95M$142.11M$3.20B$247.10M7 Day Performance-19.01%-8.90%-5.63%-3.81%1 Month Performance-30.51%-10.51%-0.38%-6.23%1 Year PerformanceN/A-12.80%7.72%-1.89% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma1.1935 of 5 stars$2.30-4.2%N/AN/A$8.40M$226,000.00-0.0217Earnings ReportUpcoming EarningsGap UpBRNSBarinthus Biotherapeutics2.2178 of 5 stars$1.03+4.0%$5.17+401.6%-59.1%$41.44M$14.97M-0.69107Short Interest ↑LTRNLantern Pharma0.7465 of 5 stars$3.90+2.1%N/A-59.8%$41.20MN/A-2.1920Earnings ReportXLOXilio Therapeutics3.3173 of 5 stars$0.79-0.5%$4.00+409.1%-32.9%$40.68M$6.34M-0.4670Upcoming EarningsShort Interest ↓Gap UpATRAAtara Biotherapeutics4.0113 of 5 stars$6.94+4.7%$17.75+155.8%-65.8%$40.66M$128.94M-0.27330SCYXSCYNEXIS1.238 of 5 stars$1.04flatN/A-35.2%$40.54M$3.75M-1.4160Gap DownDYAIDyadic International2.2605 of 5 stars$1.37-2.8%$6.00+338.0%-19.2%$40.54M$3.36M-5.967Earnings ReportFBLGFibroBiologics1.9685 of 5 stars$1.11flat$13.00+1,071.2%-91.7%$40.41MN/A0.0010Upcoming EarningsNews CoverageGap UpMDCXMedicus PharmaN/A$3.26-1.8%$10.00+206.7%N/A$39.57MN/A0.00N/AEarnings ReportPositive NewsGap UpPRLDPrelude Therapeutics2.7518 of 5 stars$0.72+1.3%$4.00+455.6%-83.8%$39.19M$7M-0.40120Positive NewsGap DownSRZNSurrozen3.3997 of 5 stars$12.00-3.6%$38.50+220.8%-25.8%$39M$10M0.0080News CoverageGap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Barinthus Biotherapeutics Competitors Lantern Pharma Competitors Xilio Therapeutics Competitors Atara Biotherapeutics Competitors SCYNEXIS Competitors Dyadic International Competitors FibroBiologics Competitors Medicus Pharma Competitors Prelude Therapeutics Competitors Surrozen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRAW Stock Free TRAW Stock Alerts